Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has been accepted for podium ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

which is aimed at treating oral lichen planus (OLP). The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg, 0.50mg and 1.0mg dose cohorts at seven trial sites in ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...

which is aimed at treating oral lichen planus (OLP). The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg, 0.50mg and 1.0mg dose cohorts at seven trial sites in the US ...